← Back to Search

CAR T-cell Therapy

Treatment (pembrolizumab, HER2Bi-armed activated T cells) for Prostate Cancer

Phase 2

Waitlist Available

Led By Abhinav Deol, M.D.

Research Sponsored by Barbara Ann Karmanos Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 6 months

Awards & highlights

Study Summary

This trial is testing a new combination of drugs to treat prostate cancer that has spread. The drugs may help to kill cancer cells.

Eligible Conditions

Castration-resistant Prostate Cancer
Low Testosterone
Prostate Cancer
Prostate-Specific Antigen

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Progression-free Survival

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (pembrolizumab, HER2Bi-armed activated T cells)Experimental Treatment3 Interventions

Patients receive pembrolizumab IV over 30 minutes every 3 weeks. Treatment repeats every 3 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity. Beginning at least 1 week after pembrolizumab, patients receive HER2Bi-armed activated T cells IV over 5-15 minutes 2 times a week for 4 weeks in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Muromonab

FDA approved

Pembrolizumab

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Barbara Ann Karmanos Cancer InstituteLead Sponsor

163 Previous Clinical Trials

9,241 Total Patients Enrolled

15 Trials studying Prostate Cancer

1,071 Patients Enrolled for Prostate Cancer

National Cancer Institute (NCI)NIH

13,662 Previous Clinical Trials

40,925,866 Total Patients Enrolled

561 Trials studying Prostate Cancer

507,095 Patients Enrolled for Prostate Cancer

Abhinav Deol, M.D.5.02 ReviewsPrincipal Investigator - Barbara Ann Karmanos Cancer Institute

Barbara Ann Karmanos Cancer Institute

3 Previous Clinical Trials

56 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What potential deleterious effects might a patient experience as a result of using pembrolizumab and HER2Bi-armed activated T cells?

"Our team at Power judged the safety of Treatment (pembrolizumab, HER2Bi-armed activated T cells) to be a 2 on a scale from 1-3 due to its Phase 2 status. This indicates that there is evidence for safety but no data as yet demonstrating efficacy."

Answered by AI

Have there been any reports regarding the efficacy of pembrolizumab and HER2Bi-armed activated T cells in prior research?

"To date, there are 975 clinical trials for Treatment (pembrolizumab, HER2Bi-armed activated T cells) underway - including 126 in Phase 3. Of these studies, several take place in Houston while the remainder span over 37,567 locations worldwide."

Answered by AI

What are pembrolizumab and HER2Bi-armed activated T cells primarily utilized to address?

"Pembrolizumab and HER2Bi-armed activated T cells have been used to treat malignant neoplasms. Additionally, this treatment could be considered for those with unresectable melanoma, microsatellite instability high, or cancer progression after chemotherapy."

Answered by AI

To what extent has participation in this investigation increased?

"At this moment, no new patients are being enrolled in this trial. It was originally posted on June 7th 2018 and last updated October 25th 2022. If you're looking for another study to participate in, there are currently 3646 trials regarding prostate cancer and 975 studies involving pembrolizumab/HER2Bi-armed activated T cells actively taking enrollees."

Answered by AI

Are any spaces available for participants in this experimentation?

"This clinical trial has since closed its recruitment period. It was initially launched on June 7th 2018 and last updated October 25th 2022. For those searching for other similar studies, there are currently 3646 trials recruiting prostate cancer patients and 975 trials looking for participants to receive the Treatment (pembrolizumab, HER2Bi-armed activated T cells)."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Abhinav Deol 2018. "Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03406858.